Rett Syndrome: Mecasermin (rh-IGF-1) treatment is safe and well-tolerated

The results from Boston Children's Hospital's Phase 1 human clinical trial in Rett syndrome have been released. A team of investigators successfully completed a Phase 1 clinical trial using mecasermin [recombinant human insulin-like growth factor 1 (IGF-1)], showing proof-of-principle that treatments like IGF-1 which are based on the neurobiology of Rett syndrome, are possible.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Pediatrics / Children's Health Source Type: news